These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728 [TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072 [TBL] [Abstract][Full Text] [Related]
9. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492 [TBL] [Abstract][Full Text] [Related]
10. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487 [TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension. Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339 [TBL] [Abstract][Full Text] [Related]
12. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Horn A; Kireva T; Palumbo-Zerr K; Dees C; Tomcik M; Cordazzo C; Zerr P; Akhmetshina A; Ruat M; Distler O; Beyer C; Schett G; Distler JH Ann Rheum Dis; 2012 May; 71(5):785-9. PubMed ID: 22402139 [TBL] [Abstract][Full Text] [Related]
15. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Beyer C; Distler JH; Distler O Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513 [TBL] [Abstract][Full Text] [Related]
16. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Weingärtner S; Zerr P; Tomcik M; Palumbo-Zerr K; Distler A; Dees C; Beyer C; Shankar SL; Cedzik D; Schafer PH; Distler O; Schett G; Distler JH Ann Rheum Dis; 2012 Nov; 71(11):1895-9. PubMed ID: 22904257 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Iwamoto N; Distler JH; Distler O Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889 [TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Distler JH; Distler O Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744 [TBL] [Abstract][Full Text] [Related]
19. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Distler JH; Distler O Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126 [TBL] [Abstract][Full Text] [Related]